{"id":417,"date":"2019-12-27T14:15:50","date_gmt":"2019-12-27T13:15:50","guid":{"rendered":"https:\/\/www.praenaforyou.com\/?page_id=417"},"modified":"2020-03-04T14:57:36","modified_gmt":"2020-03-04T13:57:36","slug":"research-and-development","status":"publish","type":"page","link":"https:\/\/www.praenaforyou.com\/en\/eurofins-lifecodexx\/research-and-development\/","title":{"rendered":"Research and Development"},"content":{"rendered":"\n
\"\"<\/figure><\/div>\n\n\n\n

Research and Development<\/h2>\n\n\n\n

Eurofins LifeCodexx \u2013 NIPT pioneer since 2010<\/h3>\n\n\n\n

Since 2010 we have been developing clinically validated, non-invasive genetic tests. Two years later, we launched PrenaTest®<\/sup>, the first non-invasive prenatal test (NIPT) in Europe. At that time it could determine trisomy 21, which leads to the Down syndrome. Now the PrenaTest®<\/sup> is able examine the complete set of chromosomes for possible changes. Of course, we will also endeavor to remain at the forefront of this field well into the future. <\/p>\n\n\n\n

<\/div><\/div>
\n

Nov 2019<\/p><\/div>\n

PrenaTest®<\/sup> now available for the detection of rare autosomal aneuploidy (rare autosomal aneuploidy, RAA). These are monosomies of chromosomes 13, 18 and 21 as well as monosomies and trisomies of chromosomes 1-12, 14-17, 19, 20 and 22.<\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Nov 2019<\/p><\/div><\/div><\/div>\n\n\n\n

Sept 2018<\/p><\/div>\n

Market launch of the PraenaRhD \u2013 Non-invasive prenatal RhD genotyping from maternal blood <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Sept 2018<\/p><\/div><\/div><\/div>\n\n\n\n

Aug 2017<\/p><\/div>\n

5 years PrenaTest®<\/sup> \u2013 More than 80,000 successfully performed PrenaTest®<\/sup> analyzes in Germany with blood samples of pregnant women from 50 countries in Europe, the Middle East and Asia <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Aug 2017<\/p><\/div><\/div><\/div>\n\n\n\n

Dec 2016<\/p><\/div>\n

CE approval for qPCR-based NIPT solution for the detection of fetal trisomy 21 (qNIPT)<\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Dec 2016<\/p><\/div><\/div><\/div>\n\n\n\n

Nov 2016<\/p><\/div>\n

Prospective clinical follow-up study with over 2,200 patients: Confirmation of the excellent test quality of the PrenaTest®<\/sup> <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Nov 2016<\/p><\/div><\/div><\/div>\n\n\n\n

May 2015<\/p><\/div>\n

PrenaTest®<\/sup> now also for the determination of the 22q11.2 microdeletion <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

May 2015<\/p><\/div><\/div><\/div>\n\n\n\n

Dec 2014<\/p><\/div>\n

Start of development of a qPCR-based NIPT assay (qNIPT) with the aim of further reducing the test price and waiting time to the test result <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Dec 2014<\/p><\/div><\/div><\/div>\n\n\n\n

Sep 2014<\/p><\/div>\n

Start of the development of an innovative NIPT data analysis system (PrenaBoxx®<\/sup>). <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Sep 2014<\/p><\/div><\/div><\/div>\n\n\n\n

Jun 2014<\/p><\/div>\n

PrenaTest®<\/sup> now also determines sex chromosomal aneuploidy (Turner, Triple X, Klinefelter and XYY syndrome) <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Jun 2014<\/p><\/div><\/div><\/div>\n\n\n\n

Feb 2014<\/p><\/div>\n

PrenaTest®<\/sup> now also applicable to twin pregnancies <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Feb 2014<\/p><\/div><\/div><\/div>\n\n\n\n

Oct 2013<\/p><\/div>\n

Reduction of the waiting time to the test result to one week by introducing the PrenaTest®<\/sup>express<\/em> <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Oct 2013<\/p><\/div><\/div><\/div>\n\n\n\n

Jul 2013<\/p><\/div>\n

PrenaTest®<\/sup> now ready for use after the ninth week of pregnancy has been completed(week 9+0 since LMP)
Introduction of the proprietary QuantYfeX®<\/sup> assay to measure the fetal fraction upon
sample receipt<\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Jul 2013<\/p><\/div><\/div><\/div>\n\n\n\n

Feb 2013<\/p><\/div>\n

PrenaTest®<\/sup> now also determines fetal trisomies 13 and 18<\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Feb 2013<\/p><\/div><\/div><\/div>\n\n\n\n

Aug 2012<\/p><\/div>\n

Market launch of the PrenaTest®<\/sup> \u2013 Europe\u2019s first NIPT \u2013 for the determination of fetal trisomy 21 from gestational week 12+0 since LMP <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Aug 2012<\/p><\/div><\/div><\/div>\n\n\n\n

Jun 2012<\/p><\/div>\n

CE Marking of proprietary bioinformatic analysis software (PrenaTest®<\/sup> DAP.plus) according to European IVD Directive <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Jun 2012<\/p><\/div><\/div><\/div>\n\n\n\n

Sep 2011<\/p><\/div>\n

License agreement with Sequenom Inc. (USA) for the acquisition of rights of use of essential patents as a legal requirement for the conduct of non-invasive prenatal tests (NIPT) in Germany <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Sep 2011<\/p><\/div><\/div><\/div>\n\n\n\n

Apr 2010<\/p><\/div>\n

Start of operative work on research and development of innovative and clinically validated non-invasive genetic tests <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Apr 2010<\/p><\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n

Press release<\/a><\/div>\n\n\n\n
Strategic partner<\/a><\/div>\n\n\n\n
Career<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Research and Development Eurofins LifeCodexx \u2013 NIPT pioneer since 2010 Since 2010 we have been developing clinically validated, non-invasive genetic tests. Two years later, we launched PrenaTest®, the first non-invasive prenatal test (NIPT) in Europe. At that time it could determine trisomy 21, which leads to the Down syndrome. Now the PrenaTest® is able examine the
… read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"ghostkit_customizer_options":"","ghostkit_custom_css":"","ghostkit_custom_js_head":"","ghostkit_custom_js_foot":"","ghostkit_typography":""},"acf":[],"_links":{"self":[{"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/pages\/417"}],"collection":[{"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/comments?post=417"}],"version-history":[{"count":0,"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/pages\/417\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/www.praenaforyou.com\/en\/wp-json\/wp\/v2\/media?parent=417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}